Michele Cavo

List of Publications by Year in Descending Order

802 papers	36,751 citations	91 h-index	180 g-index
906 ext. papers	44,324 ext. citations	4.9 avg, IF	6.58 L-index

#	Paper	IF	Citations
802	Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 15	7	1
801	Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.. *OncoTargets and Therapy*, **2022**, 15, 103-116	4.4	1
800	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.. *Lancet Haematology,the*, **2022**,	14.6	7
799	Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel.. *Critical Reviews in Oncology/Hematology*, **2022**, 172, 103623	7	0
798	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.. *Lancet Oncology, The*, **2022**,	21.7	10
797	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.. *Advances in Therapy*, **2022**, 1	4.1	1
796	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.. *Leukemia*, **2022**,	10.7	5
795	Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.. *Frontiers in Oncology*, **2022**, 12, 851864	5.3	0
794	Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity.. *Leukemia Research*, **2022**, 116, 106819	2.7	0
793	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.. *Lancet Haematology,the*, **2022**,	14.6	3
792	Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney. *Toxins*, **2022**, 14, 391	4.9	
791	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. *Annals of Hematology*, **2021**, 100, 2261-2268	3	3
790	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. *Leukemia*, **2021**, 35, 2102-2107	10.7	2
789	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. *Haematologica*, **2021**, 106, 1943-1956	6.6	28
788	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. *Haematologica*, **2021**, 106, 291-294	6.6	7
787	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.. *Frontiers in Immunology*, **2021**, 12, 804988	8.4	0
786	An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera.. *Frontiers in Oncology*, **2021**, 11, 715217	5.3	2

785	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. *Blood*, **2021**, 138, 3792-3792	2.2	
784	IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease. *Blood*, **2021**, 138, 4446-4446	2.2	
783	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥ Prior Lines of Therapy. *Blood*, **2021**, 138, 3057-3057	2.2	1
782	Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents. *Blood*, **2021**, 138, 3373-3373	2.2	
781	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. *Blood*, **2021**, 138, 115-115	2.2	0
780	Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial. *Blood*, **2021**, 138, 1662-1662	2.2	0
779	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea. *Blood*, **2021**, 138, 2581-2581	2.2	1
778	An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients. *Blood*, **2021**, 138, 2340-2340	2.2	
777	Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms. *Blood*, **2021**, 138, 3626-3626	2.2	
776	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). *Blood*, **2021**, 138, 1634-1634	2.2	
775	Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. *Blood*, **2021**, 138, 3673-3673	2.2	
774	High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy. *Blood*, **2021**, 138, 4732-4732	2.2	0
773	Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers. *Blood*, **2021**, 138, 3471-3471	2.2	0
772	Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. *Blood*, **2021**, 138, 1657-1657	2.2	
771	Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial. *Blood*, **2021**, 138, 1664-1664	2.2	3
770	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. *Blood*, **2021**, 138, 2729-2729	2.2	0
769	Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. *Blood*, **2021**, 138, 84-84	2.2	3
768	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. *Lancet Oncology, The*, **2021**, 22, 1705-1720	21.7	15

767	Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?. *Cancers*, **2021**, 13,	6.6	2
766	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. *Blood Advances*, **2021**,	7.8	4
765	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. *Expert Review of Hematology*, **2021**, 1-14	2.8	0
764	INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Advances*, **2021**,	7.8	5
763	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. *Lancet Haematology,the*, **2021**, 8, e934-e946	14.6	9
762	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *HemaSphere*, **2021**, 5, e528	0.3	19
761	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *British Journal of Haematology*, **2021**, 194, 496-507	4.5	12
760	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. *Hematological Oncology*, **2021**, 39, 409-418	1.3	3
759	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e119-e130	21.7	33
758	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e105-e118	21.7	32
757	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2021**, 32, 309-322	10.3	69
756	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. *Leukemia and Lymphoma*, **2021**, 62, 1897-1906	1.9	1
755	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. *Biomedicines*, **2021**, 9,	4.8	3
754	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. *Journal of Hematology and Oncology*, **2021**, 14, 59	22.4	6
753	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. *Cancer*, **2021**, 127, 2657-2665	6.4	7
752	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. *Blood*, **2021**, 138, 571-583	2.2	4
751	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. *American Journal of Hematology*, **2021**, 96, 708-718	7.1	9
750	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. *Journal of Clinical Oncology*, **2021**, 39, 8042-8042	2.2	3

749	Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement. *Acta Haematologica*, **2021**, 144, 688-692	2.7	
748	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. *Blood Cancer Journal*, **2021**, 11, 106	7	14
747	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. *Leukemia*, **2021**, 35, 2813-2826	10.7	3
746	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. *BMC Cancer*, **2021**, 21, 659	4.8	1
745	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet, The*, **2021**, 397, 2361-2371	40	46
744	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 785-798	2	2
743	Systemic Mastocytosis: Molecular Landscape and Implications for Treatment. *Mediterranean Journal of Hematology and Infectious Diseases*, **2021**, 13, e2021046	3.2	1
742	The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report. *Hematology Reports*, **2021**, 13, 8814	0.9	
741	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 801-812	21.7	35
740	Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma. *Lancet, The*, **2021**, 397, 2311-2313	40	
739	The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
738	Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. *Blood*, **2021**,	2.2	12
737	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. *Haematologica*, **2021**, 106, 1079-1085	6.6	8
736	Standardization of F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 116-125	2.2	31
735	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood*, **2021**, 137, 1154-1165	2.2	18
734	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. *Hematological Oncology*, **2021**, 39, 41-50	1.3	7
733	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. *British Journal of Haematology*, **2021**, 193, 356-368	4.5	8
732	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 757-767	2.2	43

731	Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma. *Leukemia and Lymphoma*, **2021**, 62, 1007-1009	1.9	0
730	Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction. *British Journal of Haematology*, **2021**, 192, e48-e51	4.5	8
729	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*, **2021**, 35, 31-44	10.7	39
728	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 619-631	4.9	5
727	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **2021**, 193, 271-279	4.5	1
726	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. *Blood Cancer Journal*, **2021**, 11, 4	7	16
725	Distinct profile of CD34 cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 49	12.8	3
724	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *New England Journal of Medicine*, **2021**, 384, 705-716	59.2	287
723	Sunitinib Exerts Immunomodulatory Activity on Sarcomas Dendritic Cells and Synergizes With PD-1 Blockade. *Frontiers in Immunology*, **2021**, 12, 577766	8.4	4
722	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. *Leukemia Research*, **2021**, 101, 106497	2.7	1
721	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. *American Journal of Hematology*, **2021**, 96, E383-E386	7.1	1
720	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. *Haematologica*, **2021**, 106, 2799-2812	6.6	4
719	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. *American Journal of Hematology*, **2021**, 96, 1120-1130	7.1	5
718	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. *Blood*, **2021**,	2.2	5
717	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. *British Journal of Haematology*, **2021**, 195, 371-377	4.5	15
716	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 2430-2442	2.2	18
715	Skeletal Survey in Multiple Myeloma: Role of Imaging. *Current Medical Imaging*, **2021**, 17, 956-965	1.2	0
714	Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. *Frontiers in Oncology*, **2021**, 11, 728613	5.3	2

713	An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. *Blood Advances*, **2021**,	7.8	3
712	Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study. *Journal of Infection*, **2021**, 83, 371-380	18.9	1
711	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 3613-3622	2.2	3
710	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. *Advances in Therapy*, **2021**, 38, 1328-1341	4.1	1
709	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.. *Cancer Medicine*, **2021**,	4.8	2
708	Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies.. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12606	5.1	0
707	ALL-073: Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT). *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, S161	2	0
706	CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, S236-S237	2	
705	MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) □ Final Primary Analysis. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, S295-S296	2	
704	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. *Lancet, The*, **2020**, 396, 1563-1573	40	92
703	Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients. *Journal of Clinical Medicine*, **2020**, 9,	5.1	8
702	Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. *Acta Haematologica*, **2020**, 143, 594-597	2.7	1
701	Disease-Specific Derangement of Circulating Endocannabinoids and -Acylethanolamines in Myeloproliferative Neoplasms. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
700	Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	10
699	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. *European Journal of Haematology*, **2020**, 105, 35-46	3.8	4
698	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. *European Journal of Haematology*, **2020**, 105, 47-55	3.8	1
697	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. *Blood Cancer Journal*, **2020**, 10, 35	7	10
696	Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. *BMC Cancer*, **2020**, 20, 170	4.8	7

695	Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. *Hematological Oncology*, **2020**, 38, 487-492	1.3	4
694	Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report. *Clinical Case Reports (discontinued)*, **2020**, 8, 933-937	0.7	0
693	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). *Leukemia*, **2020**, 34, 1840-1852	10.7	30
692	Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma. *Bone Marrow Transplantation*, **2020**, 55, 1865-1867	4.4	0
691	Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. *British Journal of Haematology*, **2020**, 189, 860-868	4.5	2
690	Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study. *British Journal of Haematology*, **2020**, 189, e6-e9	4.5	3
689	Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. *Hematological Oncology*, **2020**, 38, 201-203	1.3	2
688	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised,	14.6	114
687	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematology,the*, **2020**, 7, e370-e380	14.6	98
686	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. *Hematological Oncology*, **2020**, 38, 372-380	1.3	7
685	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. *Leukemia*, **2020**, 34, 3019-3027	10.7	5
684	Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. *Frontiers in Immunology*, **2020**, 11, 489	8.4	30
683	Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. *Blood*, **2020**, 136, 6-7	2.2	
682	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. *Blood*,	2.2	2
681	Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses. *Blood*, **2020**, 136, 45-45	2.2	
680	A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals That Fludarabine Has Weak Immunogenic Capacity and Induces T Regulatory Cells. *Blood*, **2020**, 136, 5-5	2.2	
679	Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. *Blood*, **2020**, 136, 45-46	2.2	3
678	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. *Blood*, **2020**, 136, 35-37	2.2	26

677	A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform. *Blood*, **2020**, 136, 34-37	2.2	7
676	Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study. *Blood*, **2020**, 136, 50-52	2.2	1
675	Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients. *Blood*, **2020**, 136, 39-40	2.2	5
674	Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study. *Blood*, **2020**, 136, 33-34	2.2	1
673	Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, e15-e17	2	1
672	A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT). *Leukemia and Lymphoma*, **2020**, 61, 714-720	1.9	3
671	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. *Cancer*, **2020**, 126, 1243-1252	6.4	51
670	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet, The*, **2020**, 395, 132-141	40	173
669	The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. *Bone Marrow Transplantation*, **2020**, 55, 946-954	4.4	3
668	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60´years. *Thrombosis Research*, **2020**, 185, 88-95	8.2	4
667	Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. *Cell Metabolism*, **2020**, 32, 829-843.e9	24.6	36
666	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. *Advances in Therapy*, **2020**, 37, 4996-5009	4.1	1
665	The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis. *OncoImmunology*, **2020**, 9, 1782575	7.2	6
664	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. *Lancet Haematology,the*, **2020**, 7, e861-e873	14.6	19
663	Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. *Frontiers in Oncology*, **2020**, 10, 1225	5.3	5
662	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematology,the*, **2020**, 7, e737-e745	14.6	223
661	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 1630-1642	21.7	110
660	Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. *Cancer Medicine*, **2020**, 9, 7830-7836	4.8	4

659	A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
658	Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience. *Hematological Oncology*, **2020**, 38, 737-741	1.3	3
657	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. *Journal of Hematology and Oncology*, **2020**, 13, 115	22.4	15
656	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. *Haematologica*, **2020**, 105, 468-477	6.6	27
655	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. *Haematologica*, **2020**, 105, 193-200	6.6	12
654	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. *Blood*, **2020**, 135, 534-541	2.2	37
653	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. *Blood Advances*, **2020**, 4, 830-844	7.8	21
652	Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. *Clinical Lymphoma, Myeloma*	2	5
651	HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, S329-S330	2	2
650	Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e595-e596	2	2
649	Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 995-1003	4.7	34
648	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. *Annals of Hematology*, **2019**, 98, 1933-1936	3	2
647	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncology, The*, **2019**, 20, e302-e312	21.7	166
646	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. *European Journal of Haematology*, **2019**, 103, 107-115	3.8	12
645	Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 216	12.8	9
644	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. *Current Hematologic Malignancy Reports*, **2019**, 14, 187-196	4.4	6
643	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 781-794	21.7	150
642	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. *Hematological Oncology*, **2019**, 37, 418-423	1.3	2

641	PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series. *Haematologica*, **2019**, 104, e521-e522	6.6	3
640	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. *Journal of Infection*, **2019**, 78, 484-490	18.9	13
639	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. *Leukemia*, **2019**, 33, 2276-2290	10.7	17
638	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *Journal of Internal Medicine*, **2019**, 286, 63-74	10.8	26
637	Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. *Haematologica*, **2019**, 104, 1640-1647	6.6	16
636	Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. *Mycoses*, **2019**, 62, 1100-1107	5.2	13
635	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. *Lancet Haematology,the*, **2019**, 6, e448-e458	14.6	100
634	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. *Lancet Haematology,the*, **2019**, 6, e459-e469	14.6	104
633	V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. *OncoTargets and Therapy*, **2019**, 12, 4807-4812	4.4	2
632	Multiple Myeloma: Clinical Aspects **2019**, 1-13		1
631	Spontaneous remission of follicular lymphoma. *Hematological Oncology*, **2019**, 37, 626-627	1.3	3
630	A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e31	2	16
629	The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. *Frontiers in Oncology*, **2019**, 9, 1135	5.3	21
628	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet, The*, **2019**, 394, 2096-2107	40	253
627	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. *Blood Reviews*, **2019**, 34, 84-94	11.1	19
626	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. *Frontiers in Oncology*, **2019**, 9, 1004	5.3	13
625	The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma. *Blood*, **2019**, 134, 3056-3056	2.2	1
624	Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study. *Blood*, **2019**, 134, 3480-3480	2.2	2

623	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. *Blood*, **2019**, 134, 859-859	2.2	15
622	A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE). *Blood*, **2019**, 134, 2144-2144	2.2	1
621	Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients. *Blood*, **2019**, 134, 4322-4322	2.2	9
620	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. *Blood*, **2019**, 134, 1803-1803	2.2	3
619	MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. *Blood*, **2019**, 134, 4321-4321	2.2	3
618	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. *Blood*, **2019**, 134, 605-605	2.2	2
617	Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2019**, 134, 1888-1888	2.2	29
616	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. *Blood*, **2019**, 134, 142-142	2.2	20
615	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. *Blood*, **2019**, 134, 4145-4145	2.2	2
614	Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival. *Blood*, **2019**, 134, 855-855	2.2	5
613	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. *Blood*, **2019**, 134, 661-661	2.2	3
612	Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma. *Blood*, **2019**, 134, 1778-1778	2.2	1
611	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. *Journal of Clinical Oncology*, **2019**, 37, 8002-8002	2.2	52
610	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. *Journal of Clinical Oncology*, **2019**, 37, 8040-8040	2.2	1
609	PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS. *HemaSphere*, **2019**, 3, 662-663	0.3	
608	PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE. *HemaSphere*, **2019**, 3, 1036	0.3	
607	PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS. *HemaSphere*, **2019**, 3, 254-255	0.3	
606	PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL □ANALYSIS FROM THE TOURMALINE-MM3 STUDY. *HemaSphere*, **2019**, 3, 632-633	0.3	

605	A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis. *Blood*, **2019**, 134, 1797-1797	2.2	
604	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study). *Blood*, **2019**, 134, 1881-1881	2.2	
603	Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis. *Blood*, **2019**, 134, 2143-2143	2.2	
602	Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. *Blood*, **2019**, 134, 1773-1773	2.2	0
601	Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study. *Blood*, **2019**, 134, 5580-5580	2.2	
600	Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma. *Blood*, **2019**, 134, 1796-1796	2.2	
599	The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience. *Blood*, **2019**, 134, 5098-5098	2.2	
598	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. *Blood*, **2019**, 134, 4166-4166	2.2	
597	In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. *Blood*, **2019**, 134, 4204-4204	2.2	
596	Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone. *Blood*, **2019**, 134, 3177-3177	2.2	
595	The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna. *Blood*, **2019**, 134, 4005-4005	2.2	
594	Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2332-2332	2.2	
593	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 1343-1343	2.2	
592	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. *Blood*, **2019**, 134, 4184-4184	2.2	
591	The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In VivoJAK1/2 Inhibition. *Blood*, **2019**, 134, 1686-1686	2.2	
590	The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. *Blood*, **2019**, 134, 5549-5549	2.2	0
589	AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA). *Blood*, **2019**, 134, 2617-2617	2.2	
588	Interferon-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment. *Blood*, **2019**, 134, 1212-1212	2.2	2

587	Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients. *Blood*, **2019**, 134, 3372-3372	2.2	
586	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. *Blood*, **2019**, 134, 4142-4142	2.2	
585	An IDO1-Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia. *Blood*, **2019**, 134, 5193-5193	2.2	
584	PS1395 COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE. *HemaSphere*, **2019**, 3, 640	0.3	1
583	Insights on Multiple Myeloma Treatment Strategies. *HemaSphere*, **2019**, 3, e163	0.3	23
582	S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM). *HemaSphere*, **2019**, 3, 739	0.3	1
581	PS1420 RESULTS FROM A POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED WITH NON‐LENALIDOMIDE-BASED TREATMENT IN TRANSPLANT-INELIGIBILE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. *HemaSphere*, **2019**, 3, 653-654	0.3	
580	Facing lenalidomide-refractory myeloma. *Blood*, **2019**, 134, 99-101	2.2	3
579	PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. *HemaSphere*, **2019**, 3, 37-38	0.3	
578	PB1726 DOUBLE FLUDARABINE-BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE.. *HemaSphere*, **2019**, 3, 794	0.3	
577	Front-line treatment of multiple myeloma.. *HemaSphere*, **2019**, 3,	0.3	3
576	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. *HemaSphere*, **2019**, 3, 616	0.3	0
575	Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	30
574	Imaging in multiple myeloma: How? When?. *Blood*, **2019**, 133, 644-651	2.2	41
573	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. *Cancer*, **2019**, 125, 750-760	6.4	26
572	Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. *British Journal of Haematology*, **2019**, 185, 987-991	4.5	9
571	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. *Cancer*, **2019**, 125, 712-725	6.4	33
570	Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. *British Journal of Haematology*, **2019**, 184, 424-430	4.5	10

569	Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. *British Journal of Haematology*, **2019**, 185, 981-984	4.5	12
568	A case report of the long treatment experience of a S□ary syndrome responder patient: 16 years through all the systemic and innovative therapies. *Hematological Oncology*, **2019**, 37, 202-204	1.3	0
567	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. *Annals of Hematology*, **2019**, 98, 889-896	3	4
566	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet, The*, **2019**, 393, 253-264	40	131
565	Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. *Bone Marrow Transplantation*, **2019**, 54, 717-725	4.4	10
564	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*, **2018**, 32, 1609-1620	10.7	50
563	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. *Hematological Oncology*, **2018**, 36, 561	1.3	38
562	Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. *Leukemia and Lymphoma*, **2018**, 59, 2990-2993	1.9	5
561	Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. *Haematologica*, **2018**, 103, e277-e278	6.6	21
560	Treatment of Transplant Eligible Patients with Multiple Myeloma. *Hematologic Malignancies*, **2018**, 29-60	0	1
559	Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 297-299	2	
558	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. *Expert Review of Hematology*, **2018**, 11, 219-237	2.8	21
557	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 712-719	8.8	61
556	The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies. *British Journal of Radiology*, **2018**, 91, 20170220	3.4	7
555	Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. *Molecular Cancer*, **2018**, 17, 49	42.1	103
554	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*, **2018**, 32, 1542-1560	10.7	40
553	Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. *Expert Review of Hematology*, **2018**, 11, 423-435	2.8	15
552	Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. *Supportive Care in Cancer*, **2018**, 26, 2075-2090	3.9	15

551	A targeted proteomics approach to amyloidosis typing. *Clinical Mass Spectrometry*, **2018**, 7, 18-28	1.9	1
550	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. *Leukemia*, **2018**, 32, 2032-2036	10.7	7
549	Comparison of JAK2 -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. *Hematological Oncology*, **2018**, 36, 269-275	1.3	6
548	Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. *Hematological Oncology*, **2018**, 36, 285-290	1.3	19
547	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. *Leukemia*, **2018**, 32, 139-148	10.7	17
546	Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia. *Mycoses*, **2018**, 61, 53-60	5.2	8
545	Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2450-2458	4.7	6
544	Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). *Haematologica*, **2018**, 103, 1422-1432	6.6	44
543	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. *Journal of Hematology and Oncology*, **2018**, 11, 99	22.4	24
542	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. *British Journal of Haematology*, **2018**, 183, 35-46	4.5	6
541	Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in and models. *Haematologica*, **2018**, 103, e602-e606	6.6	
540	Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34 Cells. *Mediators of Inflammation*, **2018**, 2018, 5974613	4.3	3
539	A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. *BMC Cancer*, **2018**, 18, 645	4.8	3
538	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. *Seminars in Hematology*, **2018**, 55, 248-255	4	13
537	The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience. *American Journal of Hematology*, **2018**, 93, E209	7.1	1
536	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*, **2018**, 32, 1697-1712	10.7	61
535	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2018**, 132, 155-155	2.2	17
534	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. *Blood*, **2018**, 132, 156-156	2.2	16

533	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. *Blood*, **2018**, 132, 257-257	2.2	16
532	Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. *Blood*, **2018**, 132, 305-305	2.2	25
531	Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study. *Blood*, **2018**, 132, 2288-2288	2.2	4
530	Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM). *Blood*, **2018**, 132, 121-121	2.2	39
529	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. *Blood*, **2018**, 132, 3288-3288	2.2	8
528	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. *Blood*, **2018**, 132, 124-124	2.2	31
527	OP-106 Horizon Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. *Blood*, **2018**, 132, 600-600	2.2	9
526	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). *Blood*, **2018**, 132, 1994-1994	2.2	7
525	A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide. *Blood*, **2018**, 132, 3551-3551	2.2	1
524	Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis. *Blood*, **2018**, 132, 4741-4741	2.2	2
523	Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial. *Blood*, **2018**, 132, 801-801	2.2	19
522	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. *Blood*, **2018**, 132, 3244-3244	2.2	1
521	Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. *Blood*, **2018**, 132, 685-685	2.2	24
520	Quantitative Assessment of Indoleamine 2,3-Dioxygenase (IDO) Expression at Diagnosis Predicts Clinical Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. *Blood*, **2018**, 132, 5261-5261	2.2	2
519	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. *Blood*, **2018**, 132, 4277-4277	2.2	8
518	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. *Blood*,	2.2	9
517	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. *Blood*, **2018**, 132, 4078-4078	2.2	1
516	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. *Blood*, **2018**, 132, 789-789	2.2	2

515	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. *Blood*, **2018**, 132, 44-44	2.2	6
514	Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study. *Blood*, **2018**, 132, 4365-4365	2.2	1
513	Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group. *Blood*, **2018**, 132, 3277-3277	2.2	2
512	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. *Blood*, **2018**, 132, 458-458	2.2	2
511	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. *Blood*, **2018**, 132, 3186-3186	2.2	3
510	Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. *Journal of Clinical Oncology*, **2018**, 36, 8031-8031	2.2	1
509	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. *Journal of Clinical Oncology*, **2018**, 36, e20024-e20024	2.2	2
508	Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2018**, 36, TPS8055-TPS8055	2.2	16
507	Extramedullary metastatic plasmacytoma in multiple myeloma. *Giornale Italiano Di Dermatologia E Venereologia*, **2018**, 153, 741-743	0.8	
506	Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients. *Blood*, **2018**, 132, 2433-2433	2.2	
505	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. *Blood*, **2018**, 132, 3052-3052	2.2	
504	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. *Blood*, **2018**, 132, 5284-5284	2.2	
503	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. *Blood*, **2018**, 132, 1726-1726	2.2	
502	Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients. *Blood*, **2018**, 132, 4036-4036	2.2	
501	Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. *Blood*, **2018**, 132, 2748-2748	2.2	
500	Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells. *Blood*, **2018**, 132, 2560-2560	2.2	
499	Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. *Blood*, **2018**, 132, 4347-4347	2.2	
498	The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles. *Blood*, **2018**, 132, 4334-4334	2.2	

497	Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies. *Blood*, **2018**, 132, 1507-1507	2.2	
496	Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling. *Blood*, **2018**, 132, 2579-2579	2.2	
495	Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs. *Blood*, **2018**, 132, 3235-3235	2.2	
494	Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM). *Blood*, **2018**, 132, 3550-3550	2.2	
493	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. *Blood*, **2018**, 132, 4303-4303	2.2	1
492	Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. *Blood*, **2018**, 132, 1990-1990	2.2	
491	Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation. *Blood*, **2018**, 132, 2639-2639	2.2	1
490	Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. *Blood*, **2018**, 132, 3240-3240	2.2	
489	Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study. *Blood*, **2018**, 132, 2098-2098	2.2	
488	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. *Blood*, **2018**, 132, 1779-1779	2.2	0
487	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. *Haematologica*, **2018**, 103, 197-211	6.6	78
486	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. *New England Journal of Medicine*, **2018**, 378, 518-528	59.2	568
485	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. *Blood*, **2018**, 131, 301-310	2.2	151
484	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. *European Journal of Haematology*, **2018**, 100, 10-19	3.8	6
483	Bones in Multiple Myeloma: Imaging and Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 638-646	7.1	19
482	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. *BMC Cancer*, **2018**, 18, 1117	4.8	10
481	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. *Blood Cancer Journal*, **2018**, 8, 123	7	47
480	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. *Blood Cancer Journal*, **2018**, 8, 95	7	34

479	Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. *Haematologica*, **2018**, 103, 2079-2087	6.6	167
478	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. *Health and Quality of Life Outcomes*, **2018**, 16, 127	3	3
477	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. *Leukemia Research*, **2018**, 74, 86-88	2.7	14
476	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. *Stem Cell Research and Therapy*, **2018**, 9, 271	8.3	32
475	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica*, **2018**, 103, 1772-1784	6.6	46
474	A predictive model for risk of early grade infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. *Leukemia*, **2018**, 32, 1404-1413	10.7	28
473	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e401-e419	2	37
472	FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. *Journal of Cellular Biochemistry*, **2017**, 118, 3968-3975	4.7	8
471	A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. *American Journal of Roentgenology*, **2017**, 209, 152-158	5.4	20
470	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. *Clinical Cancer Research*, **2017**, 23, 3980-3993	12.9	51
469	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *American Journal of Hematology*, **2017**, 92, 797-805	7.1	52
468	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, **2017**, 28, iv52-iv61	10.3	426
467	Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	14
466	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia*, **2017**, 31, 2443-2448	10.7	169
465	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. *European Journal of Haematology*, **2017**, 99, 199-206	3.8	15
464	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. *Haematologica*, **2017**, 102, 1530-1536	6.6	12
463	Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice. *Eye*, **2017**, 31, 1417-1426	4.4	18
462	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncology, The*, **2017**, 18, e206-e217	21.7	275

461	Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. *Haematologica*, **2017** , 102, e104-e107	6.6	10
460	Patient Characteristics, Skeletal Related Events (SRE) And Renal Impairment (RI) In Patients With Multiple Myeloma (MM): A Patient Chart Audit In EU5. *Value in Health*, **2017**, 20, A413	3.3	2
459	Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. *Annals of Hematology*, **2017**, 96, 2071-2078	3	2
458	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. *Blood*, **2017**, 130, 2610-2618	2.2	69
457	The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. *BMC Cancer*, **2017**, 17, 523	4.8	0
456	The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. *Oncotarget*, **2017**, 8, 37239-37249	3.3	11
455	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. *Neoplasia*, **2017**, 19, 750-761	6.4	14
454	Final Survival Analysis From the FIRST Trial: Lenalidomide Plus Low-Dose Dexamethasone Until Progression (Rd Cont) v Melphalan, Prednisone and Thalidomide (MPT), and Rd for 18 Cycles (Rd18) for Transplant-Ineligible (TNE) Patients (Pts) With Newly Diagnosed Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, e63-e64	2	3
453	Mutations in and genes are associated with specific alterations of the immune system in myelofibrosis. *OncoImmunology*, **2017**, 6, e1345402	7.2	25
452	Toward a GEP-based PET in myeloma. *Blood*, **2017**, 130, 2-3	2.2	20
451	Radiologic findings of Fusarium pneumonia in neutropenic patients. *Mycoses*, **2017**, 60, 73-78	5.2	10
450	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. *Annals of Oncology*, **2017**, 28, 228-245	10.3	66
449	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. *American Journal of Hematology*, **2017**, 92, 82-87	7.1	22
448	The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey. *European Journal of Cancer Care*, **2017**, 26, e12490	2.4	24
447	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. *American Journal of Hematology*, **2017**, 92, 37-41	7.1	53
446	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*, **2017**,	10.7	3
445	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. *Leukemia*, **2017**,	10.7	7
444	The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. *Oncotarget*, **2017**, 8, 2261-2274	3.3	30

443	The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia. *Frontiers in Immunology*, **2017**, 8, 1330	8.4	14
442	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. *Frontiers in Immunology*, **2017**, 8, 1918	8.4	55
441	Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials. *Blood*, **2017**, 130, 744-744	2.2	8
440	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood*, **2017**, 130, 99-99	2.2	47
439	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2017**, 35, 8003-8003	2.2	12
438	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. *Journal of Clinical Oncology*, **2017**, 35, 8006-8006	2.2	16
437	Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. *Journal of Clinical Oncology*, **2017**, 35, 8033-8033	2.2	3
436	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. *Oncotarget*, **2017**, 8, 5895-5908	3.3	32
435	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. *Oncotarget*, **2017**, 8, 29906-29913	3.3	14
434	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget*, **2017**, 8, 79073-79086	3.3	38
433	Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia. *Oncotarget*, **2017**, 8, 88244-88250	3.3	4
432	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. *Leukemia*, **2016**, 30, 417-22	10.7	96
431	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 414-21	8.8	68
430	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. *Haematologica*, **2016**, 101, 872-8	6.6	18
429	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncology, The*, **2016**, 17, e328-e346	21.7	1155
428	Multiple myeloma: disease response assessment. *Expert Review of Hematology*, **2016**, 9, 831-7	2.8	7
427	Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. *Journal of Nephrology*, **2016**, 29, 735-746	4.8	14
426	Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma. *BMC Medical Research Methodology*, **2016**, 16, 150	4.7	12

425	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. *Haematologica*, **2016**, 101, 1200-1207	6.6	19
424	Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. *Genes Chromosomes and Cancer*, **2016**, 55, 375-88	5	3
423	Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?. *Current Fungal Infection Reports*, **2016**, 10, 78-86	1.4	5
422	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. *Leukemia and Lymphoma*, **2016**, 57, 2833-2838	1.9	23
421	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. *Clinical Cancer Research*, **2016**, 22, 1914-21	12.9	88
420	Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. *Expert Review of Hematology*, **2016**, 9, 315-23	2.8	4
419	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. *Leukemia*, **2016**, 30, 1615-9	10.7	11
418	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. *Leukemia and Lymphoma*, **2016**, 57, 2058-64	1.9	9
417	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. *Journal of Clinical Oncology*, **2016**, 34, 1544-57	2.2	204
416	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. *Blood*, **2016**, 128, 1128-1128	2.2	4
415	Final Analysis of Overall Survival from the First Trial. *Blood*, **2016**, 128, 241-241	2.2	8
414	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). *Blood*, **2016**, 128, 242-242	2.2	23
413	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2016**, 128, 243-243	2.2	3
412	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. *Blood*, **2016**, 128, 3068-3068	2.2	1
411	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. *Blood*, **2016**, 128, 3070-3070	2.2	7
410	Evaluation of Experimental Retreatment and Prolonged Therapy with Subcutaneous (SC) Bortezomib in Patients (Pts) with Multiple Myeloma in First or Second Relapse, a Randomized, Controlled, Phase 3 Study. *Blood*, **2016**, 128, 3328-3328	2.2	1
409	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. *Blood*, **2016**, 128, 4251-4251	2.2	2
408	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). *Blood*, **2016**, 128, 673-673	2.2	28

407	Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). *Blood*, **2016**, 128, 991-991	2.2	28
406	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. *Journal of Clinical Oncology*, **2016**, 34, 8000-8000	2.2	43
405	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget*, **2016**, 7, 21982-90	3.3	39
404	Crucial factors of the inflammatory microenvironment (IL-1β/TNF-β/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. *Oncotarget*, **2016**, 7, 43974-43988	3.3	16
403	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. *Blood*, **2016**, 128, 3097-3097	2.2	
402	A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs. *Blood*, **2016**, 128, 2080-2080	2.2	0
401	Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells. *Blood*, **2016**, 128, 3711-3711	2.2	
400	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2016**, 128, 2134-2134	2.2	
399	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. *Blood*, **2016**, 128, 992-992	2.2	
398	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. *Blood*, **2016**, 128, 5464-5464	2.2	
397	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. *Blood*, **2016**, 128, 3336-3336	2.2	
396	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. *Blood*, **2016**, 128, 995-995	2.2	
395	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. *Blood*, **2016**, 128, 4414-4414	2.2	
394	Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. *Blood*, **2016**, 128, 5625-5625	2.2	
393	Bone Marrow Reticulin Fibrosis in 579 Patients with Polycythemia Vera and Essential Thrombocythemia: Effect on Clinical Outcome. *Blood*, **2016**, 128, 3130-3130	2.2	
392	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. *Blood*, **2016**, 128, 3076-3076	2.2	
391	Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrf Commpass Study in Newly Diagnosed Multiple Myeloma Patients. *Blood*, **2016**, 128, 2079-2079	2.2	
390	Signals of the Inflammatory Microenvironment Promote a Mutation-Associated Functional Dysregulation of the Circulating Megakaryocyte Progenitors of Myelofibrosis. *Blood*, **2016**, 128, 3142-3142	2.2	

389	Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. *Blood*, **2016**, 128, 3169-3169	2.2	
388	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. *Blood*, **2016**, 128, 3136-3136	2.2	1
387	Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly. *Mediators of Inflammation*, **2016**, 2016, 5860657	4.3	17
386	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). *Oncotarget*, **2016**, 7, 9666-79	3.3	16
385	Multiple myeloma: practice patterns across Europe. *British Journal of Haematology*, **2016**, 175, 66-76	4.5	64
384	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. *American Journal of Hematology*, **2016**, 91, 617-22	7.1	10
383	FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. *American Journal of Hematology*, **2016**, 91, E14-6	7.1	2
382	Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. *American Journal of Hematology*, **2016**, 91, E267-72	7.1	50
381	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer*, **2016**, 16, 572	4.8	15
380	Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. *Leukemia*, **2016**, 30, 1869-76	10.7	6
379	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs*, **2016**, 76, 853-67	12.1	26
378	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *New England Journal of Medicine*, **2016**, 374, 1621-34	59.2	684
377	Together for better?. *Blood*, **2016**, 127, 375-6	2.2	1
376	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. *Blood*, **2016**, 128, 497-503	2.2	117
375	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. *British Journal of Haematology*, **2016**, 174, 160-2	4.5	6
374	Multiple myeloma: patient outcomes in real-world practice. *British Journal of Haematology*, **2016**, 175, 252-264	4.5	140
373	Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. *Journal of Clinical Oncology*, **2015**, 33, 657-64	2.2	262
372	Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. *Bone Marrow Transplantation*, **2015**, 50, 673-8	4.4	15

371	Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data. *Leukemia and Lymphoma*, **2015**, 56, 559-67	1.9	11
370	The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1068-73	4.7	36
369	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology*, **2015**, 33, 2863-9	2.2	976
368	High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. *Clinical Infectious Diseases*, **2015** , 60, 1603-10	11.6	65
367	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. *Leukemia*, **2015**, 29, 1344-9	10.7	48
366	PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. *Clinical Cancer Research*, **2015**, 21, 4384-90	12.9	108
365	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica*, **2015**, 100, 1146-50	6.6	29
364	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. *Haematologica*, **2015**, 100, 1334-9	6.6	34
363	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia*, **2015**, 29, 1823-31	10.7	64
362	European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica*, **2015**, 100, 1254-66	6.6	222
361	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 2039-2051	4.7	114
360	Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. *Leukemia*, **2015**, 29, 2429-31	10.7	45
359	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. *Experimental Hematology*, **2015**, 43, 974-985.e1	3.1	19
358	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2015**, 33, 3459-66	2.2	104
357	Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. *Translational Research*, **2015**, 165, 641-50	11	34
356	Four phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma in the newly-diagnosed, relapsed/refractory, and maintenance settings: TOURMALINE-MM1, -MM2, -MM3, and -MM4. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e174	2	4
355	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. *Stem Cell Research and Therapy*, **2015**, 6, 64	8.3	14
354	Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis. *Stem Cell Research and Therapy*, **2015**, 6, 170	8.3	21

353	Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. *American Journal of Hematology*, **2015**, 90, 647-52	7.1	27
352	14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. *PLoS ONE*, **2015**, 10, e0131074	3.7	8
351	PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. *Journal of Immunology Research*, **2015**, 2015, 253191	4.5	34
350	The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. *Journal of Immunology Research*, **2015**, 2015, 526195	4.5	6
349	Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms. *Annals of Hematology*, **2015**, 94, 1585-7	3	10
348	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. *Haematologica*, **2015**, 100, 1327-33	6.6	63
347	Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Annals of Oncology*, **2015**, 26, 185-192	10.3	48
346	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. *Blood*, **2015**, 126, 1606-1606	2.2	2
345	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. *Blood*, **2015**, 126, 2792-2792	2.2	0
344	Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU). *Blood*, **2015**, 126, 2807-2807	2.2	2
343	BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?. *Blood*, **2015**, 126, 346-346	2.2	3
342	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. *Blood*, **2015**, 126, 4085-4085	2.2	1
341	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2015**, 126, 4225-4225	2.2	3
340	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study	2.2	26
339	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. *Blood*, **2015**, 126, 730-730	2.2	15
338	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. *Oncotarget*, **2015**, 6, 31284-94	3.3	15
337	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. *Blood*, **2015**, 126, 3198-3198	2.2	
336	Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2600-2600	2.2	

335	Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3837-3837	2.2	
334	The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis. *Blood*, **2015**, 126, 2394-2394	2.2	
333	Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010). *Blood*, **2015**, 126, 5376-5376	2.2	
332	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. *Blood*, **2015**, 126, 1614-1614	2.2	
331	P2X7 Receptor Activation By ATP As Target of Novel Therapies in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3684-3684	2.2	
330	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2513-2513	2.2	
329	Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2015**, 126, 1834-1834	2.2	
328	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. *Blood*, **2015**, 126, 5009-5009	2.2	
327	Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2015**, 126, 1968-1968	2.2	
326	Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters. *Blood*, **2015**, 126, 2489-2489	2.2	2
325	Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study. *Blood*, **2015**, 126, 2871-2871	2.2	1
324	Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells. *Blood*, **2015**, 126, 4094-4094	2.2	
323	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. *Blood*, **2015**, 126, 1019-1019	2.2	
322	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. *Blood*, **2015**, 126, 3840-3840	2.2	
321	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. *Blood*, **2015**, 126, 927-927	2.2	
320	Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia. *Blood*, **2015**, 126, 1573-1573	2.2	
319	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 2478-2478	2.2	
318	An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival. *Blood*, **2015**, 126, 24-24	2.2	

317	Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk. *Blood*, **2015**, 126, 1191-1191	2.2	
316	Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma. *Blood*, **2015**, 126, 2725-2725	2.2	1
315	Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. *Leukemia*, **2014**, 28, 1705-15	10.7	162
314	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. *American Journal of Hematology*, **2014**, 89, 355-62	7.1	17
313	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. *Blood*, **2014**, 123, 3414-9	2.2	51
312	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncology, The*, **2014**, 15, 333-42	21.7	206
311	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *Journal of Clinical Oncology*, **2014**, 32, 587-600	2.2	255
310	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
309	HIF-1 inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. *Experimental Cell Research*, **2014**, 328, 444-55	4.2	20
308	The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. *British Journal of Haematology*, **2014**, 165, 441-54	4.5	77
307	European perspective on multiple myeloma treatment strategies in 2014. *Oncologist*, **2014**, 19, 829-44	5.7	77
306	Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. *American Journal of Hematology*, **2014**, 89, 1085-91	7.1	37
305	Initial treatment of transplant-eligible patients in multiple myeloma. *Expert Review of Hematology*, **2014**, 7, 43-53	2.8	12
304	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *Journal of Clinical Oncology*, **2014**, 32, 634-40	2.2	171
303	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer*, **2014**, 120, 1002-9	6.4	92
302	First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. *Drugs*, **2014**, 74, 627-43	12.1	17
301	Autologous transplantation and maintenance therapy in multiple myeloma. *New England Journal of Medicine*, **2014**, 371, 895-905	59.2	539
300	Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *New England Journal of Medicine*, **2014**, 371, 906-17	59.2	565

299	Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, e101-4	2	9
298	Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. *Journal of Clinical Oncology*, **2014**, 32, 2173-80	2.2	128
297	Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. *Haematologica*, **2014**, 99, e242-3	6.6	6
296	Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. *Oncotarget*, **2014**, 5, 1779-93	3.3	38
295	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. *Leukemia*, **2014**, 28, 1573-85	10.7	84
294	The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. *Leukemia and Lymphoma*, **2014**, 55, 2665-8	1.9	1
293	Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. *Expert Review of Anticancer Therapy*, **2014**, 14, 581-94	3.5	5
292	Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. *Haematologica*, **2014**, 99, 172-9	6.6	21
291	IMWG consensus on risk stratification in multiple myeloma. *Leukemia*, **2014**, 28, 269-77	10.7	387
290	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *Haematologica*, **2014**, 99, 232-42	6.6	146
289	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. *Annals of Hematology*, **2014**, 93, 123-8	3	12
288	Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM. *Blood*, **2014**, 124, 1182-1182	2.2	2
287	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. *Blood*, **2014**, 124, 1881-1881	2.2	2
286	Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study. *Blood*, **2014**, 124, 196-196	2.2	3
285	Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients. *Blood*, **2014**, 124, 197-197	2.2	5
284	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. *Blood*, **2014**, 124, 2042-2042	2.2	1
283	The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease. *Blood*, **2014**, 124, 3371-3371	2.2	2
282	Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study. *Blood*, **2014**, 124, 4648-4648	2.2	3

281	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). *Blood*, **2014**, 124, 4755-4755	2.2	8
280	Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome. *Blood*, **2014**, 124, 484-484	2.2	2
279	Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. *Blood*, **2014**, 124, 80-80	2.2	1
278	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, TPS8625-TPS8625	2.2	1
277	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. *Blood*, **2014**, 124, 4532-4532	2.2	
276	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. *Blood*, **2014**, 124, 4770-4770	2.2	
275	Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing. *Blood*, **2014**, 124, 2259-2259	2.2	
274	High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance. *Blood*, **2014**, 124, 2054-2054	2.2	
273	Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial. *Blood*, **2014**, 124, 2033-2033	2.2	
272	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. *Blood*, **2014**, 124, 1856-1856	2.2	
271	Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. *Blood*, **2014**, 124, 3190-3190	2.2	
270	In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants. *Blood*, **2014**, 124, 815-815	2.2	
269	Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. *Blood*, **2014**, 124, 3141-3141	2.2	
268	Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells. *Blood*, **2014**, 124, 624-624	2.2	
267	A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2014**, 124, 3400-3400	2.2	
266	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. *Annals of Hematology*, **2013**, 92, 1271-80	3	3
265	Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. *Expert Review of Hematology*, **2013**, 6, 563-74	2.8	18
264	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *Journal of Clinical Oncology*, **2013**, 31, 2347-57	2.2	245

263	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. *Blood*, **2013**, 122, 1634-48	2.2	127
262	Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. *Journal of Clinical Oncology*, **2013**, 31, 3279-87	2.2	199
261	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 1055-1066	21.7	586
260	Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2013**, 54, 1975-81	1.9	15
259	Una valutazione economica di due sequenze terapeutiche nel trattamento del mieloma multiplo ricaduto e/o refrattario. *Pharmacoeconomics Italian Research Articles*, **2013**, 15, 1-8		
258	Role of consolidation therapy in transplant eligible multiple myeloma patients. *Seminars in Oncology*, **2013**, 40, 610-7	5.5	9
257	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*, **2013**, 27, 780-91	10.7	222
256	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. *Leukemia*, **2013**, 27, 711-7	10.7	149
255	Update on the treatment of Ph-negative myeloproliferative neoplasms. *International Journal of Hematologic Oncology*, **2013**, 2, 251-262	1	1
254	Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. *British Journal of Haematology*, **2013**, 161, 291-4	4.5	3
253	Cap dependent translation contributes to resistance of myeloma cells to bortezomib. *Translation*, **2013**, 1, e27245		3
252	Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. *Tumori*, **2013**, 99, e193-e202	1.7	11
251	The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. *Clinical Nuclear Medicine*, **2013**, 38, e74-9	1.7	51
250	Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib. *Blood*, **2013**, 122, 1859-1859	2.2	1
249	PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients. *Blood*, **2013**, 122, 1936-1936	2.2	2
248	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT). *Blood*, **2013**, 122, 2-2	2.2	28
247	Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study. *Blood*, **2013**, 122, 2090-2090	2.2	5
246	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. *Blood*, **2013**, 122, 258-258	2.2	2

245	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). *Blood*, **2013**, 122, 3198-3198	2.2	1
244	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. *Blood*, **2013**, 122, 380-380	2.2	2
243	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 408-408	2.2	8
242	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 686-686	2.2	1
241	Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity. *Blood*, **2013**, 122, 752-752	2.2	1
240	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. *Blood*, **2013**, 122, 767-767	2.2	48
239	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. *Journal of Clinical Oncology* , **2013**, 31, 8517-8517	2.2	6
238	A risk prediction score for invasive mold disease in patients with hematological malignancies. *PLoS ONE*, **2013**, 8, e75531	3.7	45
237	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. *Blood*, **2013**, 122, 1486-1486	2.2	
236	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. *Blood*, **2013**, 122, 4000-4000	2.2	
235	Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4. *Blood*, **2013**, 122, 1855-1855	2.2	
234	Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma. *Blood*, **2013**, 122, 398-398	2.2	
233	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). *Blood*, **2013**, 122, 3185-3185	2.2	
232	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. *Blood*, **2013**, 122, 3986-3986	2.2	
231	Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs). *Blood*, **2013**, 122, 2074-2074	2.2	
230	Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. *Tumori*, **2013**, 99, e193-202	1.7	6
229	Primary plasma cell leukemia in the era of new drugs: has something changed?. *Critical Reviews in Oncology/Hematology*, **2012**, 82, 141-9	7	17
228	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. *Cancer*, **2012**, 118, 1574-84	6.4	79

227	Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. *Annals of Hematology*, **2012**, 91, 419-26	3	9
226	IMWG consensus on maintenance therapy in multiple myeloma. *Blood*, **2012**, 119, 3003-15	2.2	150
225	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood*, **2012**, 119, 933-9; quiz 1093	2.2	212
224	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. *Blood*, **2012**, 120, 9-19	2.2	277
223	The role of imaging techniques in the management of multiple myeloma. *British Journal of Haematology*, **2012**, 159, 499-513	4.5	82
222	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
221	MyelomA Genetics International Consortium. *Leukemia and Lymphoma*, **2012**, 53, 796-800	1.9	7
220	Contrast enhanced MRI and ^{18}F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. *European Journal of Radiology*, **2012**, 81, 4013-8	4.7	80
219	Proteasome inhibitors in multiple myeloma: 10 years later. *Blood*, **2012**, 120, 947-59	2.2	370
218	Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia*, **2012**, 26, 595-608	10.7	189
217	Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *New England Journal of Medicine*, **2012**, 366, 1759-69	59.2	578
216	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. *Annals of Hematology*, **2012**, 91, 875-88	3	27
215	Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. *Bone Marrow Transplantation*, **2012**, 47, 1248-9	4.4	5
214	European perspective on multiple myeloma treatment strategies: update following recent congresses. *Oncologist*, **2012**, 17, 592-606	5.7	43
213	Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma. *Blood*, **2012**, 120, 4210-4210	2.2	1
212	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. *Blood*, **2012**, 120, 749-749	2.2	8
211	The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair. *Blood*, **2012**, 120, 1810-1810	2.2	
210	The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping. *Blood*, **2012**, 120, 199-199	2.2	1

209	Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical Trials. *Blood*, **2012**, 120, 594-594	2.2	
208	SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1 in Multiple Myeloma. *Blood*, **2012**, 120, 574-574	2.2	
207	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. *Cancer Treatment Reviews*, **2011**, 37, 266-83	14.4	62
206	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood*, **2011**, 117, 4696-700	2.2	252
205	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood*, **2011**, 117, 6063-73	2.2	234
204	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). *Blood*, **2011**, 118, 4519-29	2.2	267
203	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. *Blood*, **2011**, 118, 5989-95	2.2	357
202	A third-generation IMiD for MM. *Blood*, **2011**, 118, 2931-2	2.2	10
201	Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *Journal of Clinical Oncology*, **2011**, 29, 986-93	2.2	253
200	Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. *Seminars in Thrombosis and Hemostasis*, **2011**, 37, 209-19	5.3	56
199	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. *Blood*, **2011**, 118, 5759-66	2.2	31
198	Patient with ataxia telangiectasia who developed acute myeloid leukemia. *Leukemia and Lymphoma* , **2011**, 52, 1818-20	1.9	6
197	Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. *Oncologist*, **2011**, 16, 388-403	5.7	23
196	Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). *Blood*, **2011**, 118, 1871-1871	2.2	2
195	HIF 1 Alpha: A Suitable Target for Multiple Myeloma. *Blood*, **2011**, 118, 2901-2901	2.2	2
194	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients . *Blood*, **2011**, 118, 3069-3069	2.2	7
193	Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2011**, 118, 317-317	2.2	2
192	High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53,. *Blood*, **2011**, 118, 3935-3935	2.2	1

191	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015. *Blood*, **2011**, 118, 475-475	2.2	8
190	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. *Blood*, **2011**, 118, 480-480	2.2	15
189	Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD). *Blood*, **2011**, 118, 1821-1821	2.2	
188	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma. *Blood*, **2011**, 118, 1867-1867	2.2	
187	Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications. *Blood*, **2011**, 118, 826-826	2.2	
186	A Score Model for Predicting Unsuccessful or Sub-Optimal Peripheral Blood Stem Cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction Therapy and Cyclophosphamide Plus G-CSF As Mobilizing Regimen,. *Blood*, **2011**, 118, 4044-4044	2.2	
185	A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). *Blood*, **2011**, 118, 805-805	2.2	
184	Survival and years of life lost in different age cohorts of patients with multiple myeloma. *Journal of Clinical Oncology*, **2010**, 28, 1599-605	2.2	113
183	Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist*, **2010**, 15, 6-25	5.7	77
182	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. *Leukemia and Lymphoma*, **2010**, 51, 2006-11	1.9	13
181	Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. *Journal of Clinical Oncology*, **2010**, 28, 4976-84	2.2	290
180	Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1115-21	4.7	28
179	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet, The*, **2010**, 376, 2075-85	40	672
178	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. *Leukemia and Lymphoma*, **2010**, 51, 1424-43	1.9	43
177	How I treat elderly patients with myeloma. *Blood*, **2010**, 116, 2215-23	2.2	33
176	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. *Blood*, **2010**, 116, 3743-50	2.2	91
175	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. *Blood*, **2010**, 116, 4745-53	2.2	325
174	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. *European Journal of Haematology*, **2010**, 84, 223-8	3.8	62

173	Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. *European Journal of Haematology*, **2010**, 84, 484-92	3.8	22
172	Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients. *Blood*, **2010**, 116, 3562-3562	2.2	4
171	Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study. *Blood*, **2010**, 116, 42-42	2.2	4
170	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. *Blood*, **2010**, 116, 781-781	2.2	6
169	Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis. *Blood*, **2010**, 116, 861-861	2.2	5
168	Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study. *Blood*, **2010**, 116, 369-369	2.2	
167	Thalidomide maintenance in multiple myeloma: certainties and controversies. *Journal of Clinical Oncology*, **2009**, 27, e186-7; author reply e188	2.2	11
166	Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. *Journal of Clinical Oncology*, **2009**, 27, 5001-7	2.2	42
165	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. *Annals of Oncology*, **2009**, 20, 1303-17	10.3	171
164	Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. *Circulation*, **2009**, 120, 1203-12	16.7	471
163	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. *European Journal of Haematology*, **2009**, 82, 93-105	3.8	17
162	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*, **2009**, 23, 215-24	10.7	559
161	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia*, **2009**, 23, 1716-30	10.7	123
160	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia*, **2009**, 23, 1904-12	10.7	170
159	Ascorbic acid inhibits antitumor activity of bortezomib in vivo. *Leukemia*, **2009**, 23, 1679-86	10.7	82
158	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. *Blood*, **2009**, 114, 1729-35	2.2	170
157	The Activity of Spanish and Italian Myeloma Groups. *Clinical Lymphoma and Myeloma*, **2009**, 9, S36-S39		
156	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. *Clinical Lymphoma and Myeloma*, **2009**, 9, S51-S52		

155	First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. *Current Drug Targets*, **2009**, 10, 906-22	3	6
154	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. *Blood*, **2009**, 114, 1868-1868	2.2	1
153	A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.. *Blood*, **2009**, 114, 351-351	2.2	12
152	A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. *Blood*, **2009**, 114, 3852-3852	2.2	11
151	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. *Blood*, **2009**, 114, 492-492	2.2	11
150	Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II Bologna 2002 Study.. *Blood*, **2009**, 114, 349-349	2.2	
149	Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.. *Blood*, **2009**, 114, 4885-4885	2.2	
148	Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. *Blood*, **2009**, 114, 1882-1882	2.2	
147	Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.. *Blood*, **2009**, 114, 2811-2811	2.2	
146	Thalidomide and Dexamethasone as Salvage Therapy after First Relapse in Multiple Myeloma: Analysis of Long-Term Outcomes.. *Blood*, **2009**, 114, 4933-4933	2.2	
145	A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia.. *Blood*, **2009**, 114, 4951-4951	2.2	
144	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia*, **2008**, 22, 414-23	10.7	654
143	Gender-related risk of myocardial involvement in systemic amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2008**, 15, 40-8	2.7	66
142	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. *Blood*, **2008**, 111, 4039-47	2.2	153
141	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. *Blood*, **2008**, 112, 3107-14	2.2	293
140	Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. *European Journal of Haematology*, **2008**, 80, 31-6	3.8	4
139	Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. *Blood*, **2008**, 112, 158-158	2.2	13
138	Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.. *Blood*, **2008**, 112, 1662-1662	2.2	2

137	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus MelphalanPrednisone Versus MelphalanPrednisone. *Blood*, **2008**, 112, 2778-2778	2.2	10
136	A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. *Blood*, **2008**, 112, 2781-2781	2.2	13
135	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. *Blood*, **2008**, 112, 3017-3017	2.2	16
134	Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study. *Blood*, **2008**, 112, 3681-3681	2.2	1
133	Bortezomib-Thalidomide-Dexamethasone as Primary Induction Therapy for Newly Diagnosed Multiple Myeloma Significantly Decreases Bone Resorption While Sparing Bone Formation as Compared to Thalidomide-Dexamethasone. *Blood*, **2008**, 112, 5117-5117	2.2	1
132	Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study. *Blood*, **2008**, 112, 2393-2393	2.2	3
131	Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition. *Blood*, **2008**, 112, 3687-3687	2.2	
130	Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice. *Clinical Advances in Hematology and Oncology*, **2008**, 6, s4-s10	0.6	0
129	18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. *In Vivo*, **2008**, 22, 513-7	2.3	49
128	11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. *World Journal of Surgical Oncology*, **2007**, 5, 68	3.4	76
127	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. *British Journal of Haematology*, **2007**, 139, 415-24	4.5	55
126	Current status of bortezomib in the treatment of multiple myeloma. *Current Hematologic Malignancy Reports*, **2007**, 2, 128-37	4.4	9
125	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. *Haematologica*, **2007**, 92, 50-5	6.6	256
124	Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. *Journal of Clinical Oncology*, **2007**, 25, 2434-41	2.2	289
123	Neuropathy in multiple myeloma treated with thalidomide: a prospective study. *Neurology*, **2007**, 69, 573-81	6.5	108
122	Nonmyeloablative allotransplantation for myeloma: light and shade. *Blood*, **2007**, 109, 3134-3135	2.2	2
121	Prevention of VTE in multiple myeloma patients. *Thrombosis Research*, **2007**, 120 Suppl 2, S133-6	8.2	5
120	A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens.. *Blood*, **2007**, 110, 310-310	2.2	7

119	Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.. *Blood*, **2007**, 110, 447-447	2.2	2
118	Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. *Blood*, **2007**, 110, 73-73	2.2	37
117	Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96® Study.. *Blood*, **2007**, 110, 730-730	2.2	
116	Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.. *Blood*, **2007**, 110, 4728-4728	2.2	
115	Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.. *Blood*, **2007**, 110, 3997-3997	2.2	
114	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 525-31	8.8	111
113	Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 1522	8.8	14
112	Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. *Annals of Hematology*, **2006**, 85, 549-51	3	4
111	First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. *European Journal of Haematology*, **2006**, 76, 399-404	3.8	45
110	The changing landscape of myeloma therapy. *New England Journal of Medicine*, **2006**, 354, 1076-8	59.2	28
109	Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. *Journal of Clinical Oncology*, **2006**, 24, e4-5	2.2	26
108	Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. *Blood*, **2006**, 108, 3951-2	2.2	48
107	Proteasome inhibitor bortezomib for the treatment of multiple myeloma. *Leukemia*, **2006**, 20, 1341-52	10.7	105
106	International uniform response criteria for multiple myeloma. *Leukemia*, **2006**, 20, 1467-73	10.7	1996
105	Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.. *Blood*, **2006**, 108, 245-245	2.2	4
104	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. *Blood*, **2006**, 108, 3081-3081	2.2	8
103	Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).. *Blood*, **2006**, 108, 3571-3571	2.2	2
102	Bone Involvement in Multiple Myeloma Patients Carrying the T (4;14) Chromosomal Translocation.. *Blood*, **2006**, 108, 4996-4996	2.2	

101	CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.. *Blood*, **2006**, 108, 371-371	2.2	0
100	Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. *Blood*, **2005**, 106, 35-9	2.2	288
99	Myeloma therapy: the future is bright. *Blood*, **2005**, 106, 4018-4019	2.2	1
98	The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. *Bone Marrow Transplantation* , **2005**, 35, 609-17	4.4	52
97	Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. *European Journal of Haematology*, **2005**, 74, 212-6	3.8	86
96	Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.. *Blood*, **2005**, 106, 3461-3461	2.2	16
95	Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.. *Blood*, **2005**, 106, 5474-5474	2.2	
94	Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma.. *Blood*, **2005**, 106, 5072-5072	2.2	
93	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. *Blood*, **2005**, 106, 3492-3492	2.2	
92	Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor.. *Blood*, **2005**, 106, 4363-4363	2.2	
91	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. *Thrombosis and Haemostasis*, **2004**, 92, 1438-45	7	54
90	Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. *European Journal of Haematology*, **2004**, 73, 98-103	3.8	88
89	New insights into the knowledge of graft-versus-myeloma. *Blood*, **2004**, 103, 371-372	2.2	
88	Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.. *Blood*, **2004**, 104, 536-536	2.2	9
87	Thalidomide-Induced Peropheral Neuropathy in Newly Diagnosed and Pre-Treated Multiple Myeloma Patients.. *Blood*, **2004**, 104, 4898-4898	2.2	
86	Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2004**, 104, 1489-1489	2.2	1
85	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). *Haematologica*, **2004**, 89, 717-41	6.6	41
84	First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. *Haematologica*, **2004**, 89, 826-31	6.6	121

83	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. *Blood*, **2003**, 102, 1588-94	2.2	100
82	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. *Blood*, **2003**, 102, 1927-9	2.2	160
81	Relevance of cyclin D1 level in the pathogenesis of multiple myeloma. *Blood*, **2003**, 102, 4245-6; author reply 4246	2.2	8
80	Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. *Blood*, **2002**, 100, 2272-3	2.2	143
79	Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. *Haematologica*, **2002**, 87, 408-14	6.6	70
78	Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. *Haematologica*, **2002**, 87, 934-42	6.6	23
77	Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. *Haematologica*, **2002**, 87, 1036-40	6.6	11
76	Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. *British Journal of Haematology*, **2001**, 113, 209-16	4.5	259
75	Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. *Haematologica*, **2001**, 86, 409-13	6.6	23
74	Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. *Leukemia*, **2000**, 14, 22-7	10.7	25
73	Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. *Leukemia*, **2000**, 14, 1310-3	10.7	56
72	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. *Blood*, **2000**, 96, 355-357	2.2	86
71	Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. *Journal of Clinical Oncology*, **2000**, 18, 2273-81	2.2	133
70	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. *Blood*, **2000**, 95, 2234-2239	2.2	62
69	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. *Blood*, **2000**, 95, 2234-2239	2.2	2
68	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. *Blood*, **2000**, 96, 355-357	2.2	1
67	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. *Blood*, **2000**, 95, 2234-9	2.2	14
66	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. *Blood*, **2000**, 96, 355-7	2.2	25

65	Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. *Haematologica*, **2000**, 85, 930-4	6.6	25
64	In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. *European Journal of Haematology*, **1999**, 62, 143-8	3.8	13
63	Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. *British Journal of Haematology*, **1999**, 107, 419-28	4.5	20
62	Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report. *Bone Marrow Transplantation*, **1999**, 24, 685-7	4.4	11
61	Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. *Bone Marrow Transplantation*, **1999**, 24, 741-5	4.4	58
60	Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. *Haematologica*, **1999** , 84, 397-404	6.6	13
59	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. *Bone Marrow Transplantation*, **1998**, 22, 27-32	4.4	44
58	Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. *Haematologica*, **1998**, 83, 48-55	6.6	9
57	Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. *European Journal of Haematology*, **1997**, 59, 82-8	3.8	10
56	Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. *Leukemia and Lymphoma*, **1997**, 26 Suppl 1, 1-11	1.9	19
55	Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. *Blood*, **1996**, 87, 1625-1634	2.2	151
54	Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. *Blood*, **1996**, 88, 4711-4718	2.2	305
53	Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. *Stem Cells and Development*, **1996**, 5, 339-49		20
52	Plasma cell P170 expression and response to treatment in multiple myeloma. *Haematologica*, **1996**, 81, 232-7	6.6	6
51	Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. *Haematologica*, **1996**, 81, 356-75	6.6	4
50	Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. *Blood*, **1996**, 88, 4711-8	2.2	53
49	Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. *Haematologica*, **1996**, 81, 533-5	6.6	12
48	Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. *Journal of Clinical Oncology*, **1995**, 13, 1312-22	2.2	246

47	An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation. *Stem Cells*, **1995**, 13 Suppl 2, 122-5	5.8	4
46	Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. *Stem Cells*, **1995**, 13 Suppl 2, 126-31	5.8	5
45	Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. *Stem Cells*, **1995**, 13 Suppl 2, 140-6	5.8	20
44	Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities?. *Annals of Oncology*, **1995**, 6, 687-91	10.3	77
43	The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. *Best Practice and Research: Clinical Haematology*, **1995**, 8, 795-813		7
42	Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. *Leukemia and Lymphoma*, **1994**, 15, 265-72	1.9	44
41	Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. *British Journal of Haematology*, **1994**, 88, 760-9	4.5	38
40	Application of the hydraulic shaking system method to isolation of human pancreatic islets. *Transplantation Proceedings*, **1994**, 26, 3436-7	1.1	
39	Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. *European Journal of Haematology*, **1993**, 51, 93-7	3.8	24
38	A Randomized Study of MP versus Alternating VAD-VND(N=Mitoxantrone)/MP as Primary Therapy for Multiple Myeloma. *Leukemia and Lymphoma*, **1992**, 7, 75-76	1.9	
37	Allogeneic Bone Marrow Transplantation in Multiple Myeloma. *Hematology/Oncology Clinics of North America*, **1992**, 6, 425-435	3.1	9
36	Allogeneic bone marrow transplantation in multiple myeloma. *Hematology/Oncology Clinics of North America*, **1992**, 6, 425-35	3.1	2
35	Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. *New England Journal of Medicine*, **1991**, 325, 1267-73	59.2	306
34	Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119). *Blut*, **1990**, 61, 311-3		2
33	Accelerated hemopoietic recovery after chemotherapy and autologous bone marrow transplantation in hematological malignancies using recombinant GM-CSF: preliminary results obtained in 14 cases. *Haematologica*, **1990**, 75, 551-4	6.6	8
32	In vitro growth of myeloma cells. *European Journal of Haematology*, **1989**, 51, 43-6	3.8	1
31	Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: a multivariate regression analysis of 163 untreated patients. *European Journal of Haematology*, **1989**, 51, 99-104	3.8	1
30	Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. *European Journal of Haematology*, **1989**, 51, 176-81	3.8	9

29	High-dose chemoradiotherapy and allogenic bone marrow transplantation in multiple myeloma. *European Journal of Haematology*, **1989**, 51, 191-5	3.8	2
28	Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. *Cancer Chemotherapy and Pharmacology*, **1989**, 23, 123-5	3.5	7
27	Bone marrow purging for multiple myeloma by avidin-biotin immunoadsorption. *Transplantation*, **1989**, 47, 385-7	1.8	5
26	Evidence that long-term bone marrow culture of patients with multiple myeloma favors normal hemopoietic proliferation. *Transplantation*, **1989**, 48, 1026-31	1.8	10
25	Prognostic variables and clinical staging in multiple myeloma. *Blood*, **1989**, 74, 1774-1780	2.2	52
24	Normal myeloid progenitors (CFU-GM) in multiple myeloma: a preliminary study in view of autologous BMT. *Bone Marrow Transplantation*, **1989**, 4, 373-7	4.4	2
23	Prognostic variables and clinical staging in multiple myeloma. *Blood*, **1989**, 74, 1774-80	2.2	9
22	M-2 protocol for melphalan-resistant and relapsing multiple myeloma. *European Journal of Haematology*, **1988**, 40, 168-73	3.8	14
21	Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. *International Journal of Cell Cloning*, **1988**, 6, 313-23		1
20	Septicaemia after splenectomy for Hodgkin's disease: two episodes in the same patient, 9 and 13 years after cure. *Acta Haematologica*, **1988**, 80, 223	2.7	
19	Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies. *Haematologica*, **1988** , 73, 503-8	6.6	3
18	Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies. *Clinical and Experimental Immunology*, **1987**, 70, 192-200	6.2	29
17	Bone marrow transplantation in multiple myeloma. *Scandinavian Journal of Haematology*, **1986**, 36, 176-9		32
16	Solitary plasmacytoma of the bone in a case of Hodgkin's disease. *Acta Haematologica*, **1986**, 76, 178-80	2.7	4
15	Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. *Acta Haematologica*, **1985**, 74, 27-30	2.7	42
14	Meningeal leukemia complicating prolymphocytoid transformation of B-chronic lymphocytic leukemia. *Acta Haematologica*, **1985**, 74, 205-7	2.7	18
13	Lonidamine in the treatment of chronic lymphoid leukemia. *Oncology*, **1984**, 41 Suppl 1, 90-3	3.6	7
12	BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA. *British Journal of Haematology*, **1984**, 57, 352-353	4.5	3

11	BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA. *British Journal of Haematology*, **1984**, 57, 352-353	4.5	5
10	Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease. *Clinical and Experimental Immunology*, **1984**, 56, 653-8	6.2	30
9	Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen. *Clinical and Experimental Immunology*, **1984**, 58, 625-30	6.2	7
8	High-dose melphalan for multiple myeloma. *Lancet, The*, **1983**, 2, 1194	40	2
7	Secondary cutaneous plasmacytoma. *Acta Haematologica*, **1983**, 69, 287-8	2.7	8
6	Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma. *British Journal of Haematology*, **1983**, 55, 683-90	4.5	24
5	Staging of chronic lymphocytic leukemia. *Blood*, **1982**, 59, 1191-1196	2.2	59
4	Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. *Cancer*, **1982**, 49, 623-32	6.4	28
3	IgD myeloma in a young woman. *Haematologica*, **1982**, 67, 760-4	6.6	2
2	Peptichemio in multiple myeloma. (Preliminary results). *Haematologica*, **1981**, 66, 208-15	6.6	7
1	Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone. *Haematologica*, **1980**, 65, 437-45	6.6	9